0001415889-24-006079.txt : 20240301 0001415889-24-006079.hdr.sgml : 20240301 20240301161514 ACCESSION NUMBER: 0001415889-24-006079 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240228 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Berman David M CENTRAL INDEX KEY: 0001955244 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39992 FILM NUMBER: 24709917 MAIL ADDRESS: STREET 1: C/O PROVENTION BIO, INC. STREET 2: 55 BROAD STREET CITY: RED BANK STATE: NJ ZIP: 07701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunocore Holdings plc CENTRAL INDEX KEY: 0001671927 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY BUSINESS PHONE: 01235 5430281 MAIL ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY FORMER COMPANY: FORMER CONFORMED NAME: Immunocore Ltd DATE OF NAME CHANGE: 20160412 4 1 form4-03012024_040305.xml X0508 4 2024-02-28 0001671927 Immunocore Holdings plc IMCR 0001955244 Berman David M C/O IMMUNOCORE HOLDINGS PLC 92 PARK DRIVE, MILTON PARK, ABINGDON OXFORDSHIRE X0 OX14 4RY UNITED KINGDOM false true false false HEAD OF R&D 1 Ordinary Shares 2024-02-28 4 M 0 36509 17.46 A 36509 D Ordinary Shares 2024-02-28 4 S 0 16900 67.61 D 19609 D Ordinary Shares 2024-02-28 4 S 0 7472 68.84 D 12137 D Ordinary Shares 2024-02-28 4 S 0 10937 69.73 D 1200 D Ordinary Shares 2024-02-28 4 S 0 1200 70.45 D 0 D Employee Share Option (Right to Buy) 17.46 2024-02-28 4 M 0 36509 0 D 2028-09-12 Ordinary Shares 36509 271790 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.08 to $68.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.26 to $69.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.26 to $70.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.42 to $70.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Immediately exercisable. /s/ Lily Hepworth, Attorney-in-Fact 2024-03-01